Cargando…

Numerical simulation of vascular tumour growth under antiangiogenic treatment: addressing the paradigm of single-agent bevacizumab therapy with the use of experimental data

BACKGROUND: Antiangiogenic agents have been recently added to the oncological armamentarium with bevacizumab probably being the most popular representative in current clinical practice. The elucidation of the mode of action of these agents is a prerequisite for personalized prediction of antiangioge...

Descripción completa

Detalles Bibliográficos
Autores principales:	Argyri, Katerina D., Dionysiou, Dimitra D., Misichroni, Fay D., Stamatakos, Georgios S.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2016
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4804544/ https://www.ncbi.nlm.nih.gov/pubmed/27005569 http://dx.doi.org/10.1186/s13062-016-0114-9

Ejemplares similares

Introduction of Hypermatrix and Operator Notation into a Discrete Mathematics Simulation Model of Malignant Tumour Response to Therapeutic Schemes In Vivo. Some Operator Properties
por: Stamatakos, Georgios S., et al.
Publicado: (2009)

A Modular Repository-based Infrastructure for Simulation Model Storage and Execution Support in the Context of In Silico Oncology and In Silico Medicine
por: Christodoulou, Nikolaos A., et al.
Publicado: (2016)

Applying a 4D multiscale in vivo tumor growth model to the exploration of radiotherapy scheduling: The effects of weekend treatment gaps and p53 gene status on the response of fast growing solid tumors
por: Dionysiou, Dimitra D., et al.
Publicado: (2007)

Studying the regression profiles of cervical tumours during radiotherapy treatment using a patient-specific multiscale model
por: Kyroudis, Christos A., et al.
Publicado: (2019)

Differentiation resistance through altered retinoblastoma protein function in acute lymphoblastic leukemia: in silico modeling of the deregulations in the G1/S restriction point pathway
por: Ouzounoglou, Eleftherios, et al.
Publicado: (2016)

Three-dimensional tumor growth in time-varying chemical fields: a modeling framework and theoretical study
por: Antonopoulos, Markos, et al.
Publicado: (2019)

Publisher Correction to: Three-dimensional tumor growth in time-varying chemical fields: a modeling framework and theoretical study
por: Antonopoulos, Markos, et al.
Publicado: (2019)

Exploiting Clinical Trial Data Drastically Narrows the Window of Possible Solutions to the Problem of Clinical Adaptation of a Multiscale Cancer Model
por: Stamatakos, Georgios S., et al.
Publicado: (2011)

A new paradigm for antiangiogenic therapy through controlled release of bevacizumab from PLGA nanoparticles
por: Sousa, Flávia, et al.
Publicado: (2017)

AI-Enabled Smart Wristband Providing Real-Time Vital Signs and Stress Monitoring
por: Mitro, Nikos, et al.
Publicado: (2023)

Thrombospondin-1 as a Paradigm for the Development of Antiangiogenic Agents Endowed with Multiple Mechanisms of Action
por: Rusnati, Marco, et al.
Publicado: (2010)

Neoadjuvant and conversion treatment of patients with colorectal liver metastasis: the potential role of bevacizumab and other antiangiogenic agents
por: García-Alfonso, Pilar, et al.
Publicado: (2015)

DCE-MRI biomarkers in the clinical evaluation of antiangiogenic and vascular disrupting agents
por: O'Connor, J P B, et al.
Publicado: (2007)

Critical Parameters Determining Standard Radiotherapy Treatment Outcome for Glioblastoma Multiforme: A Computer Simulation
por: Dionysiou, D.D, et al.
Publicado: (2008)

Dealing with Diversity in Computational Cancer Modeling
por: Johnson, David, et al.
Publicado: (2013)

Enhanced tumour antiangiogenic effects when combining gefitinib with the antivascular agent ZD6126
por: Bozec, A, et al.
Publicado: (2006)

Workflow-driven clinical decision support for personalized oncology
por: Bucur, Anca, et al.
Publicado: (2016)

Angiogenesis and antiangiogenic agents in cervical cancer
por: Tomao, Federica, et al.
Publicado: (2014)

Risk profile for antiangiogenic agent-related osteonecrosis of the jaws
por: Caminha, Raquel D’Aquino Garcia, et al.
Publicado: (2019)

Antiangiogenic activity of aplidine, a new agent of marine origin
por: Taraboletti, G, et al.
Publicado: (2004)

Activation of hypoxia signaling induces phenotypic transformation of glioma cells: implications for bevacizumab antiangiogenic therapy
por: Xu, Hui, et al.
Publicado: (2015)

A Numerical Handling of the Boundary Conditions Imposed by the Skull on an Inhomogeneous Diffusion-Reaction Model of Glioblastoma Invasion Into the Brain: Clinical Validation Aspects
por: Stamatakos, Georgios S, et al.
Publicado: (2017)

Antiangiogenic and tumour inhibitory effects of downregulating tumour endothelial FABP4
por: Harjes, U, et al.
Publicado: (2017)

In Silico Oncology: Quantification of the In Vivo Antitumor Efficacy of Cisplatin-Based Doublet Therapy in Non-Small Cell Lung Cancer (NSCLC) through a Multiscale Mechanistic Model
por: Kolokotroni, Eleni, et al.
Publicado: (2016)

Combination oral antiangiogenic therapy with thalidomide and sulindac inhibits tumour growth in rabbits
por: Verheul, H M W, et al.
Publicado: (1999)

PPARα Ligands as Antitumorigenic and Antiangiogenic Agents
por: Pozzi, Ambra, et al.
Publicado: (2008)

VEGF(165)b, an antiangiogenic VEGF-A isoform, binds and inhibits bevacizumab treatment in experimental colorectal carcinoma: balance of pro- and antiangiogenic VEGF-A isoforms has implications for therapy
por: Varey, A H R, et al.
Publicado: (2008)

The antiangiogenic agent ZD4190 prevents tumour outgrowth in a model of minimal residual carcinoma in deep tissues
por: Gaballah, K, et al.
Publicado: (2009)

Tumoral cavitation in patients with non-small-cell lung cancer treated with antiangiogenic therapy using bevacizumab
por: Nishino, Mizuki, et al.
Publicado: (2012)

Design and Implementation of a UAV-Based Airborne Computing Platform for Computer Vision and Machine Learning Applications
por: Douklias, Athanasios, et al.
Publicado: (2022)

Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours
por: Dunn, J R, et al.
Publicado: (2006)

Pulmonary cavitation in patients with thyroid cancer receiving antiangiogenic agents
por: Datar, Saumil, et al.
Publicado: (2020)

Vascular Hysteresis Loops and Vascular Architecture Mapping in Patients with Glioblastoma treated with Antiangiogenic Therapy
por: Stadlbauer, Andreas, et al.
Publicado: (2017)

Phase II trial of the antiangiogenic agent IM862 in metastatic renal cell carcinoma
por: Deplanque, G, et al.
Publicado: (2004)

Vascular co‐option and vasculogenic mimicry mediate resistance to antiangiogenic strategies
por: Pezzella, Francesco, et al.
Publicado: (2020)

UPARANT is an effective antiangiogenic agent in a mouse model of rubeosis iridis
por: Locri, Filippo, et al.
Publicado: (2019)

Contemporary Updates on Clinical Trials of Antiangiogenic Agents in the Treatment of Glioblastoma Multiforme
por: Kochar, Arshneel Singh, et al.
Publicado: (2018)

Risk of bleeding associated with antiangiogenic monoclonal antibodies bevacizumab and ramucirumab: a meta-analysis of 85 randomized controlled trials
por: Xiao, Bingkun, et al.
Publicado: (2018)

Antiangiogenic therapy
por: Avitabile, T
Publicado: (2010)

The cost burden of trastuzumab and bevacizumab therapy for solid tumours in Canada
por: Drucker, A., et al.
Publicado: (2008)

Cannot write session to /tmp/vufind_sessions/sess_0mih6331blfmc35liq4o348l3o